News

Lighthouse Labs names new managing director

Lighthouse Labs has announced Art Espey as the new Managing Director, effective April 17. Art will replace outgoing Managing Director Paul Nolde, who will assume a similar role at Norfolk’s 757 Collab and 757 Angels organizations.

Art has long been involved with Lighthouse Labs, having previously served on the organization’s Board of Directors as Founding Vice Chair (2015 to 2018) and recently rejoining the Board. A serial entrepreneur, he has extensive experience in the full life cycle of startups, including scaling one of his ventures into a top 100 company in its industry with a staff of 500+, and gaining domestic and international leadership experience with an Inc. 500 company. His background includes work in healthcare, analytics, manufacturing, and construction, with significant experience in strategic leadership, private equity, diversity consulting, mergers and acquisitions, and business development. He holds degrees from the United States Merchant Marine Academy, Eastern Michigan University, and the University of Virginia. A former USMC Officer and Young Presidents’ Organization (YPO) member, Art has authored multiple books and taught a college-level course in change management. He currently sits on the Virginia Bio+Tech Partnership Authority Board of Directors and was formerly the Vice Chair of the American Red Cross in Southeastern Michigan. His wealth of experience will help Lighthouse Labs extend a record of success built on more than ten years of Investing in the lives of founders™. 

“After a decade, Lighthouse Labs is at an inflection point, with an opportunity to think big and reinvent our work with founders, investors, and the area’s innovation ecosystem,” Art shared. “I’m pleased to have the chance to build on the work previous leaders and the team have accomplished and look forward to continued success. I envision new and creative partnering opportunities with Paul and 757 Collab to foster innovation across the entire RVA757 megaregion.”

Nolde will continue with Lighthouse Labs through the end of the current cohort (May 30), and Art has already begun working with the team to ensure a smooth transition. Joe Kunkel, Lighthouse Labs Board Chair, stated “Lighthouse Labs has gained a stellar reputation and remained relevant by constantly refining our work to better support founders and their startups, and we are excited for the next chapter under Art’s leadership.”

 

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …